interleukin-8 and Lymphoma--T-Cell

Systemically applied agents to modulate the Fas/FasL system, e.g., by stimulation of Fas on activated leukocytes or tumor cells failed as strategies in immune therapy due to severe toxic effects in the host. Recently, a novel strategy has been developed by using immobilized immune active biologicals in a medical device that may allow immune management without expensive systemic therapy. This review reports on the potential role of Fas/FasL in immune therapy and summarizes current experimental and clinical data with the leukocyte inhibition module (LIM), an immobilized anti-Fas antibody containing device yet used in extracorporeal blood circulation. This proof of principal may stimulate the development of other devices based on the regulation of Fas/FasL or other targets relevant for immune disorders.

Topics: Animals; Apoptosis; Autoimmune Diseases; Cardiopulmonary Bypass; Equipment and Supplies; Fas Ligand Protein; fas Receptor; Humans; Immunoglobulin M; Interleukin-8; Lymphoma, T-Cell; Membrane Glycoproteins; Virus Diseases